Introduction/Background Primary tumors of the vulva and vagina are very rare and represent only a small percentage of all gynecological tumors. In both cases, the first consultation is usually late, which usually implies diagnoses in advanced stages that limit the surgical approach.

Our objective was to analyse the local control and survival after radiochemotherapy and brachytherapy in locally advanced cancer of the vulva and vagina in a series of cases treated at our centre.

Methodology We retrospectively reviewed 7 patients diagnosed with FIGO stage IVA vulvar cancer (5) and vaginal cancer (2) (figure 1), median age 58 years old, treated in our centre between 2020 and 2022. They completed treatment with Intensity-Modulated Radiation Therapy (IMRT) (dose 45 to 60 Gy, conventional fractionation) and concurrent chemotherapy, and 5 of them received complementary HDR intracavitary brachytherapy to achieve EQD2 85–90 Gy.

Results The 15-month overall survival was 85% (1 death cancer related), with locorregional and distant control in 6 patients. Only one patient with vulvar cancer had to stop treatment due to grade 3 (CTCAE v.5) radiation dermatitis, which was controlled in 2 weeks. After 24 months of follow-up, only two of them experienced significative vaginal stenosis.

• Download figure
• Open in new tab
• Download powerpoint

Abstract #194 Figure 1

Before and after treatment with radical radio-chemotherapy of vaginal cancer in a 37-year-old patient which resulted in a complete response.

Conclusion Radical radiochemotherapy is an effective and safe treatment with high local control in patients with locally advanced primary vulvar and vaginal cancer.

Disclosures The authors have no conflicts of interest to declare. All co-authors have seen and agree with the contents of the manuscript and there is no financial interest to report. We certify that the submission is original work and is not under review at any other publication.